This website uses its own and third-party cookies in order to improve the browsing experience. If you continue browsing you will be accepting expressly the use of these cookies. You can get more information on our Cookies policy page.



OSAXYL, the first PoC device for the diagnosis of hypolactasia, presented at BIOSPAIN 2018

OSASEN SENSORES, VENTER PHARMA and FERRER FARMA have launched at BIOSPAIN 2018, held 25-27 September in Seville, the OSAXYL PoC device, result of their collaboration and consisting of a precise, simple and fast solution to hipolactasia diagnosis, the cause of lactose intolerance.

OSAXYL is a Point of Care (PoC) system for the detection of xylose in urine, in a fast, easy to use and economical way, which has already been internally validated, guaranteeing its high level of precision and reliability. OSAXYL will improve the health and quality of life of people with lactose intolerance, allowing a comfortable, quick and simple diagnosis, as well as a reduction in medical care costs.

For this purpose, OSAXYL is used in combination with the diagnostic drug LacTEST® developed by VENTER PHARMA and marketed by FERRER to evaluate hypolactasia. Low levels of lactase activity will result in low levels of xylose in the urine after ingestion of LacTEST. VENTER PHARMA saw the interest in developing a PoC for the measurement of xylose in urine after the ingestion of LacTEST®, as an alternative solution to the currently available methods. This is why OSAXYL is the result of a co-development carried out by OSASEN SENSORES in collaboration with VENTER PHARMA, which will be marketed by FERRER FARMA.

OSAXYL is an enzymatic biosensor based on electrochemical detection that are presented as a powerful alternative for application to PoC devices, as they combine the high specificity of enzymes with techniques that allow the mass production of miniaturized devices. This technological application derives from a patent recently registered by OSASEN.

OSAXYL consists of a xylometer, a portable electronic reader capable of translating electrochemical signals into a quantitative xylose result, and disposable test strips, based on screen-printed electrodes (SPEs) functionalized with the specific enzyme for the measurement of xylose. OSAXYL has already had a successful reception at the Congress of the Spanish Society of Digestive Pathology, generating interesting expectations among professionals in the field of digestive diseases, which ratifies the interest and opportunity of the new product.

BIOSPAIN is the largest biotechnology event organised by a national bioindustry association in Europe and one of the largest in the world in terms of the number of individual meetings (+3,000) and participating companies (+800). The event is organized by ASEBIO, the Spanish Bioindustry Association, and each edition has been co-organized by a local institution in the host city/region, with Andalusia in this 2018 edition.

Biospain 2018_1  Biospain 2018_2